Literature DB >> 1833513

2-Nitroimidazole potentiation of nitrosourea induced cytotoxicity in subcutaneous implants of rat 9L brain tumor cells.

K H Wong1, C A Wallen, K T Wheeler.   

Abstract

To determine if the 2-nitroimidazole (2-NI) and the nitrosourea (NU) in a brain tumor chemopotentiation trial should be selected on the basis of known structure-activity relationships (electron affinity, lipophilicity, alkylating activity, carbamoylating activity), s.c. implants of rat 9L brain tumor cells were treated with combinations of misonidazole (MISO) or etanidazole (SR-2508) administered under oxic and hypoxic conditions, and BCNU, CCNU or chlorozotocin (CLZ) administered under oxic conditions. Cell kill was assessed by an in vivo to in vitro colony formation assay. To mimic the 'preincubation effect', the 2-NI was injected i.p., and 30 min later the tumor was clamped. After 2 hr, the clamp was released, and the NU administered immediately. MISO (2.5 mmole/kg) and SR-2508 (3.75 mmole/kg) reached the same peak tumor concentration in 30 min. Both 2-NIs were metabolized at the same rate in the clamped tumors; however, metabolism of the 2-NIs by hypoxic cells over the 2 hr clamping period did not produce any measurable s.c. 9L cell kill. The relative effectiveness of the NUs for killing oxic s.c. 9L tumor cells was: BCNU greater than CCNU greater than CLZ. Clamping the tumor prior to NU administration did not change the NU cytotoxicity. No potentiation of the NU cytotoxicity by the 2-NIs was observed in oxic tumors. Although metabolism of MISO by hypoxic cells did not result in potentiation of CLZ cytotoxicity at any dose, it resulted in potentiation of BCNU cytotoxicity at all doses and CCNU cytotoxicity at high doses.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1833513     DOI: 10.1007/bf00166993

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  35 in total

1.  A structure-activity analysis of chemical and biological parameters of chloroethylnitrosoureas in mice.

Authors:  L C Panasci; D Green; R Nagourney; P Fox; P S Schein
Journal:  Cancer Res       Date:  1977-08       Impact factor: 12.701

2.  Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy.

Authors:  R A Gatenby; H B Kessler; J S Rosenblum; L R Coia; P J Moldofsky; W H Hartz; G J Broder
Journal:  Int J Radiat Oncol Biol Phys       Date:  1988-05       Impact factor: 7.038

Review 3.  Modification of chemotherapy by nitroimidazoles.

Authors:  D W Siemann
Journal:  Int J Radiat Oncol Biol Phys       Date:  1984-09       Impact factor: 7.038

4.  SR-2508: a 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use.

Authors:  J M Brown; N Y Yu; D M Brown; W W Lee
Journal:  Int J Radiat Oncol Biol Phys       Date:  1981-06       Impact factor: 7.038

5.  The pharmacokinetics and tumor and neural tissue penetrating properties of SR-2508 and SR-2555 in the dog--hydrophilic radiosensitizers potentially less toxic than misonidazole.

Authors:  R A White; P Workman; J M Brown
Journal:  Radiat Res       Date:  1980-12       Impact factor: 2.841

6.  Chemosensitization of the nitrosoureas by 2-nitroimidazoles in the subcutaneous 9L tumor model: pharmacokinetic and structure-activity considerations.

Authors:  K H Wong; C A Wallen; K T Wheeler
Journal:  Int J Radiat Oncol Biol Phys       Date:  1990-05       Impact factor: 7.038

7.  Nitroimidazoles as modifiers of nitrosourea pharmacokinetics.

Authors:  F Y Lee; P Workman
Journal:  Int J Radiat Oncol Biol Phys       Date:  1984-09       Impact factor: 7.038

8.  O6-alkylguanine-DNA alkyltransferase activity in human brain and brain tumors.

Authors:  O Wiestler; P Kleihues; A E Pegg
Journal:  Carcinogenesis       Date:  1984-01       Impact factor: 4.944

9.  Misonidazole combined with hyperfractionation in the management of malignant glioma.

Authors:  D S Fulton; R C Urtasun; K H Shin; P H Geggie; H Thomas; P J Muller; J Moody; H Tanasichuk; B Mielke; E Johnson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1984-09       Impact factor: 7.038

10.  Misonidazole and CCNU: further evidence for a pharmacokinetic mechanism of chemosensitization and therapeutic gain.

Authors:  F Y Lee; P Workman
Journal:  Br J Cancer       Date:  1984-05       Impact factor: 7.640

View more
  1 in total

Review 1.  Drug resistance in brain tumors.

Authors:  L G Feun; N Savaraj; H J Landy
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.